Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
987,814
-
Share change
-
-153,518
-
Total reported value
-
$8,789,216
-
Put/Call ratio
-
1093%
-
Price per share
-
$8.90
-
Number of holders
-
21
-
Value change
-
-$1,492,870
-
Number of buys
-
8
-
Number of sells
-
11
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q2 2021
As of 30 Jun 2021,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
987,814 shares.
The largest 10 holders included
ARK Investment Management LLC, RENAISSANCE TECHNOLOGIES LLC, ACT Capital Management, LLC, Golden Green, Inc., Compagnie Lombard Odier SCmA, SUSQUEHANNA INTERNATIONAL GROUP, LLP, WELLS FARGO & COMPANY/MN, Steward Partners Investment Advisory, LLC, MORGAN STANLEY, and UBS Group AG.
This page lists
20
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.